Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $17.00

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been assigned a consensus recommendation of “Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $17.00.

Several equities research analysts have weighed in on the stock. Wedbush lowered their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. lifted its position in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new position in Voyager Therapeutics in the first quarter valued at $38,000. China Universal Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares in the last quarter. SG Americas Securities LLC purchased a new position in Voyager Therapeutics in the second quarter valued at $85,000. Finally, ProShare Advisors LLC purchased a new position in Voyager Therapeutics in the first quarter valued at $101,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Up 4.2 %

Shares of VYGR stock opened at $5.66 on Friday. The firm has a market cap of $309.21 million, a price-to-earnings ratio of 7.96 and a beta of 0.89. The company’s 50 day moving average is $6.54 and its 200 day moving average is $7.38. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the firm earned ($0.59) earnings per share. Analysts anticipate that Voyager Therapeutics will post -1.03 EPS for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.